Andres Y. Maldonado, an analyst from H.C. Wainwright, reiterated the Hold rating on Sutro Biopharma. The associated price target remains the same with $2.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Andres Y. Maldonado has given his Hold rating due to a combination of factors related to Sutro Biopharma’s strategic shift and current pipeline developments. The company is transitioning from its previous focus on single-asset value creation to a broader platform-driven approach, emphasizing next-generation antibody-drug conjugates (ADCs). This shift is exemplified by their lead internal program, STRO-004, which is expected to enter clinical development in the latter half of 2025.
While the scientific foundation of Sutro’s programs, including STRO-004 and other preclinical assets, is acknowledged, the company is in a transitional phase where significant value creation hinges on successful clinical execution. The upcoming trial for STRO-004 will be crucial in determining the effectiveness of their site-specific conjugation technology. Until these clinical outcomes are clearer, the company presents a longer-term investment story, appealing to those willing to assume preclinical risks.